Voraxaze
What Voraxaze is used for
Voraxaze is indicated to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination or at risk of methotrexate toxicity.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
- Approved under exceptional circumstances: full data cannot be collected, usually because the disease is very rare.
Key facts
- Brand
- Voraxaze
- Active substance
- glucarpidase
- Disease area
- Metabolic Side Effects of Drugs and Substances
- Medicine group
- All other therapeutic products
- ATC code
- V03AF09
- Marketing authorisation holder
- SERB SAS
- Authorised in the EU since
- 2022
Official information
In the USA
Same active substance: Voraxaze
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Voraxaze used for?
Voraxaze is indicated to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination or at risk of methotrexate toxicity.
What is the active substance in Voraxaze?
Voraxaze contains glucarpidase.
Who makes Voraxaze?
The EU marketing authorisation holder is SERB SAS.
Is Voraxaze an orphan medicine?
Yes. Voraxaze is designated an orphan medicine in the EU, for a rare disease (Metabolic Side Effects of Drugs and Substances).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU